David A Fox

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2505060/publications.pdf

Version: 2024-02-01

160 papers	11,758 citations	30047 54 h-index	30058 103 g-index
164 all docs	164 docs citations	164 times ranked	13106 citing authors

#	Article	IF	Citations
1	An alternative pathway of T-cell activation: A functional role for the 50 kd T11 sheep erythrocyte receptor protein. Cell, 1984, 36, 897-906.	13.5	1,153
2	NETs Are a Source of Citrullinated Autoantigens and Stimulate Inflammatory Responses in Rheumatoid Arthritis. Science Translational Medicine, 2013, 5, 178ra40.	5.8	1,016
3	Th17 cells in human disease. Immunological Reviews, 2008, 223, 87-113.	2.8	960
4	Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis. New England Journal of Medicine, 1985, 312, 818-822.	13.9	833
5	In Vivo Activated T Lymphocytes in the Peripheral Blood and Cerebrospinal Fluid of Patients with Multiple Sclerosis. New England Journal of Medicine, 1985, 312, 1405-1411.	13.9	310
6	Clinical and Immunologic Effects of Monthly Administration of Intravenous Cyclophosphamide in Severe Systemic Lupus Erythematosus. New England Journal of Medicine, 1988, 318, 1423-1431.	13.9	288
7	The role of T cells in the immunopathogenesis of rheumatoid arthritis. New perspectives. Arthritis and Rheumatism, 1997, 40, 598-609.	6.7	269
8	Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis. Science Immunology, 2017, 2, .	5.6	228
9	Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Research and Therapy, 2007, 9, 202.	1.6	191
10	Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. Journal of Clinical Investigation, 2001, 107, 1275-1284.	3.9	180
11	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase <scp>II</scp> Investigatorâ€Initiated, Multicenter, Doubleâ€Blind, Randomized, Placeboâ€Controlled Trial. Arthritis and Rheumatology, 2020, 72, 125-136.	2.9	163
12	Advances in the Medical Treatment of Rheumatoid Arthritis. Hand Clinics, 2011, 27, 11-20.	0.4	138
13	Top3Î² is an RNA topoisomerase that works with fragile X syndrome protein to promote synapse formation. Nature Neuroscience, 2013, 16, 1238-1247.	7.1	124
14	The functional interactions between CD98, Î²1-integrins, and CD147 in the induction of U937 homotypic aggregation. Blood, 2001, 98, 374-382.	0.6	119
15	TLRs, future potential therapeutic targets for RA. Autoimmunity Reviews, 2017, 16, 103-113.	2.5	118
16	Synovial biology and T cells in rheumatoid arthritis. Pathophysiology, 2005, 12, 183-189.	1.0	116
17	Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. Journal of Clinical Investigation, 2020, 130, 2451-2464.	3.9	106
18	Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-Î± Inhibition for Cancer and Autoimmune Disease. Cell Chemical Biology, 2017, 24, 1029-1039.e7.	2.5	104

#	Article	IF	Citations
19	Effector Function of Resting T Cells: Activation of Synovial Fibroblasts. Journal of Immunology, 2001, 166, 2270-2275.	0.4	102
20	Effectiveness of rheumatoid hand surgery: Contrasting perceptions of hand surgeons and rheumatologists. Journal of Hand Surgery, 2003, 28, 3-11.	0.7	98
21	Neutrophil extracellular traps mediate articular cartilage damage and enhance cartilage component immunogenicity in rheumatoid arthritis. JCI Insight, 2020, 5, .	2.3	97
22	Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. Blood, 2014, 123, 786-793.	0.6	94
23	Targeting the Myofibroblast Genetic Switch: Inhibitors of Myocardin-Related Transcription Factor/Serum Response Factorâ€“Regulated Gene Transcription Prevent Fibrosis in a Murine Model of Skin Injury. Journal of Pharmacology and Experimental Therapeutics, 2014, 349, 480-486.	1.3	92
24	UM4D4+ (CDw60) T Cells Are Compartmentalized into Psoriatic Skin and Release Lymphokines That Induce a Keratinocyte Phenotype Expressed in Psoriatic Lesions. Journal of Investigative Dermatology, 1990, 95, 275-282.	0.3	91
25	Synovial cellular and molecular markers in rheumatoid arthritis. Seminars in Immunopathology, 2017, 39, 385-393.	2.8	89
26	Presentation of arthritogenic peptide to antigen-specific T cells by fibroblast-like synoviocytes. Arthritis and Rheumatism, 2007, 56, 1497-1506.	6.7	88
27	Membrane-Type I Matrix Metalloproteinase-Dependent Regulation of Rheumatoid Arthritis Synoviocyte Function. Journal of Immunology, 2010, 184, 6396-6406.	0.4	87
28	Effects of administration of an anti-cd5 plus immunoconjugate in rheumatoid arthritis. results of two phase ii studies. Arthritis and Rheumatism, 1993, 36, 620-630.	6.7	86
29	T-Lymphocyte Clones Initiated from Lesional Psoriatic Skin Release Growth Factors that Induce Keratinocyte Proliferation. Journal of Investigative Dermatology, 1993, 101, 695-700.	0.3	86
30	T cell subsets and their role in the pathogenesis of rheumatic disease. Current Opinion in Rheumatology, 2014, 26, 204-210.	2.0	85
31	Abnormalities in CD4+ T-lymphocyte subsets in inflammatory rheumatic diseases. American Journal of Medicine, 1988, 84, 817-825.	0.6	84
32	Reduced Fas ligand-expressing splenic CD5+ B lymphocytes in severe collagen-induced arthritis. Arthritis Research and Therapy, 2009, 11, R128.	1.6	78
33	Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3695-3702.	3.3	77
34	Regulation of pathogenic IL-17 responses in collagen-induced arthritis: roles of endogenous interferon-gamma and IL-4. Arthritis Research and Therapy, 2009, 11, R158.	1.6	76
35	The role of T helper type 17 cells in inflammatory arthritis. Clinical and Experimental Immunology, 2010, 159, 225-237.	1.1	75
36	DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis. Nature Communications, 2017, 8, 14252.	5.8	75

#	Article	IF	Citations
37	Validity and responsiveness of the Michigan hand questionnaire in patients with rheumatoid arthritis: A multicenter, international study. Arthritis Care and Research, 2010, 62, 1569-1577.	1.5	74
38	Endothelial dysfunction in rat adjuvant-induced arthritis: Vascular superoxide production by NAD(P)H oxidase and uncoupled endothelial nitric oxide synthase. Arthritis and Rheumatism, 2006, 54, 1847-1855.	6.7	73
39	Targeting IL-17 and Th17 Cells in Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 2010, 36, 345-366.	0.8	71
40	A Multicenter Clinical Trial in Rheumatoid Arthritis Comparing Silicone Metacarpophalangeal Joint Arthroplasty With Medical Treatment. Journal of Hand Surgery, 2009, 34, 815-823.	0.7	70
41	CD6 as a potential target for treating multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2687-2692.	3.3	70
42	Human B Cell-Derived Lymphoblastoid Cell Lines Constitutively Produce Fas Ligand and Secrete MHCII+FasL+ Killer Exosomes. Frontiers in Immunology, 2014, 5, 144.	2.2	69
43	Sensitivity and Resistance to Regulation by IL-4 during Th17 Maturation. Journal of Immunology, 2011, 187, 4440-4450.	0.4	68
44	CD318 is a ligand for CD6. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6912-E6921.	3.3	67
45	Cytokine Blockade as a New Strategy to Treat Rheumatoid Arthritis. Archives of Internal Medicine, 2000, 160, 437.	4.3	66
46	Cell-cell Interactions in Rheumatoid Arthritis Synovium. Rheumatic Disease Clinics of North America, 2010, 36, 311-323.	0.8	66
47	Fluvastatin reverses endothelial dysfunction and increased vascular oxidative stress in rat adjuvant-induced arthritis. Arthritis and Rheumatism, 2007, 56, 1827-1835.	6.7	64
48	Historical Perspective on the Etiology of Rheumatoid Arthritis. Hand Clinics, 2011, 27, 1-10.	0.4	63
49	Responsiveness of human T lymphocytes to bacterial superantigens presented by cultured rheumatoid arthritis synoviocytes. Arthritis and Rheumatism, 1996, 39, 125-136.	6.7	62
50	Molecular Interactions between T Cells and Fibroblast-Like Synoviocytes. American Journal of Pathology, 2007, 171, 1588-1598.	1.9	62
51	Interactions of T Cells with Fibroblast-Like Synoviocytes: Role of the B7 Family Costimulatory Ligand B7-H3. Journal of Immunology, 2008, 180, 2989-2998.	0.4	62
52	Histone Deacetylase 5 Is Overexpressed in Scleroderma Endothelial Cells and Impairs Angiogenesis via Repression of Proangiogenic Factors. Arthritis and Rheumatology, 2016, 68, 2975-2985.	2.9	62
53	Activation of human T cells through CD6: functional effects of a novel anti-CD6 monoclonal antibody and definition of four epitopes of the CD6 glycoprotein. International Immunology, 1993, 5, 783-792.	1.8	61
54	Immunocompetent Properties of Human Osteoblasts: Interactions With T Lymphocytes. Journal of Bone and Mineral Research, 2005, 21, 29-36.	3.1	58

#	Article	IF	Citations
55	CD6: expression during development, apoptosis and selection of human and mouse thymocytes. International Immunology, 2002, 14, 585-597.	1.8	56
56	The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases. Clinical Immunology, 2017, 175, 10-15.	1.4	52
57	IL-11 facilitates a novel connection between RA joint fibroblasts and endothelial cells. Angiogenesis, 2018, 21, 215-228.	3.7	52
58	Establishing clinical severity for PROMISÂ® measures in adult patients with rheumatic diseases. Quality of Life Research, 2018, 27, 755-764.	1.5	52
59	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Annals of the Rheumatic Diseases, 2020, 79, 724-726.	0.5	51
60	Novel molecular mechanisms of dendritic cell-induced T cell activation. International Immunology, 2000, 12, 1051-1061.	1.8	50
61	Systemic Toxicity Following Administration of Sirolimus (Formerly Rapamycin) for Psoriasis. Archives of Dermatology, 1999, 135, 553-7.	1.7	49
62	Involvement of the reninâ€“angiotensin system in the development of vascular damage in a rat model of arthritis: Effect of angiotensin receptor blockers. Arthritis and Rheumatism, 2010, 62, 1319-1328.	6.7	49
63	Neutrophil-mediated carbamylation promotes articular damage in rheumatoid arthritis. Science Advances, 2020, 6, .	4.7	49
64	Interleukin-17 as a molecular target in immune-mediated arthritis: Immunoregulatory properties of genetically modified murine dendritic cells that secrete interleukin-4. Arthritis and Rheumatism, 2007, 56, 89-100.	6.7	48
65	Citrullinated calreticulin potentiates rheumatoid arthritis shared epitope signaling. Arthritis and Rheumatism, 2013, 65, 618-626.	6.7	48
66	Loss of SH3 Domainâ€“Binding Protein 2 Function Suppresses Bone Destruction in Tumor Necrosis Factorâ€“Driven and Collagenâ€Induced Arthritis in Mice. Arthritis and Rheumatology, 2015, 67, 656-667.	2.9	48
67	CD13/Aminopeptidase N Is a Potential Therapeutic Target for Inflammatory Disorders. Journal of Immunology, 2020, 204, 3-11.	0.4	48
68	Longâ€term followup for rheumatoid arthritis patients in a multicenter outcomes study of silicone metacarpophalangeal joint arthroplasty. Arthritis Care and Research, 2012, 64, 1292-1300.	1.5	45
69	Macrophages are the primary effector cells in IL-7-induced arthritis. Cellular and Molecular Immunology, 2020, 17, 728-740.	4.8	45
70	Transcriptional Profiling of Synovial Macrophages Using Minimally Invasive Ultrasoundâ€Guided Synovial Biopsies in Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 841-854.	2.9	44
71	Regulatory T cell defects in rheumatoid arthritis. Arthritis and Rheumatism, 2007, 56, 710-713.	6.7	43
72	Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1744-1749.	1.0	42

#	Article	IF	Citations
73	Role of Complement in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy. Journal of Immunology, 2018, 200, 4094-4101.	0.4	42
74	Surgical management of the rheumatoid hand: consensus and controversy among rheumatologists and hand surgeons. Journal of Rheumatology, 2003, 30, 1464-72.	1.0	41
75	Interleukin-5 Supports the Expansion of Fas Ligand-Expressing Killer B Cells that Induce Antigen-Specific Apoptosis of CD4+ T Cells and Secrete Interleukin-10. PLoS ONE, 2013, 8, e70131.	1.1	39
76	A unique role for galectin-9 in angiogenesis and inflammatory arthritis. Arthritis Research and Therapy, 2018, 20, 31.	1.6	39
77	Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies. Vaccine, 2021, 39, 6111-6116.	1.7	39
78	Killer B Lymphocytes and Their Fas Ligand Positive Exosomes as Inducers of Immune Tolerance. Frontiers in Immunology, 2015, 6, 122.	2.2	38
79	Expression and Function of Aminopeptidase N/CD13 Produced by Fibroblastâ€like Synoviocytes in Rheumatoid Arthritis: Role of CD13 in Chemotaxis of Cytokineâ€Activated T Cells Independent of Enzymatic Activity. Arthritis and Rheumatology, 2015, 67, 74-85.	2.9	38
80	Expression and Characterization of a Novel CD6 Ligand in Cells Derived from Joint and Epithelial Tissues. Journal of Immunology, 2004, 173, 6125-6133.	0.4	36
81	CD19+CD5+ B Cells in Primary IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2008, 19, 2130-2139.	3.0	36
82	Outcomes of Silicone Arthroplasty for Rheumatoid Metacarpophalangeal Joints Stratified by Fingers. Journal of Hand Surgery, 2009, 34, 1647-1652.	0.7	36
83	Cell cycle progression is associated with distinct patterns of phosphorylation of Op18. Biochemical and Biophysical Research Communications, 1992, 185, 197-203.	1.0	35
84	Crystal Structure of the BARD1 Ankyrin Repeat Domain and Its Functional Consequences. Journal of Biological Chemistry, 2008, 283, 21179-21186.	1.6	35
85	5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma. Journal of Medicinal Chemistry, 2019, 62, 4350-4369.	2.9	34
86	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. Lancet Rheumatology, The, 2020, 2, e743-e753.	2.2	34
87	Phospholipase D enzymes facilitate IL-17- and TNFÎ±-induced expression of proinflammatory genes in rheumatoid arthritis synovial fibroblasts (RASF). Immunology Letters, 2016, 174, 9-18.	1.1	33
88	Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice. Arthritis Research and Therapy, 2019, 21, 292.	1.6	31
89	IRAK4 inhibition: a promising strategy for treating RA joint inflammation and bone erosion. Cellular and Molecular Immunology, 2021, 18, 2199-2210.	4.8	31
90	Defective CD2 pathway T cell activation in systemic lupus erythematosus. Arthritis and Rheumatism, 1991, 34, 561-571.	6.7	28

#	Article	IF	Citations
91	Leukemic T Cells from Patients with Cutaneous T-Cell Lymphoma Demonstrate Enhanced Activation Through CDw60, CD2, and CD28 Relative to Activation Through the T-Cell Antigen Receptor Complex. Journal of Investigative Dermatology, 1993, 100, 667-673.	0.3	28
92	Clinical and experimental evidence for targeting CD6 in immune-based disorders. Autoimmunity Reviews, 2018, 17, 493-503.	2.5	28
93	Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds. ACS Pharmacology and Translational Science, 2019, 2, 92-100.	2.5	28
94	Biological therapies: A novel approach to the treatment of autoimmune disease. American Journal of Medicine, 1995, 99, 82-88.	0.6	27
95	A Prospective Study Comparing Outcomes after Reconstruction in Rheumatoid Arthritis Patients with Severe Ulnar Drift Deformities. Plastic and Reconstructive Surgery, 2009, 123, 1769-1777.	0.7	27
96	Kinase Inhibition â€" A New Approach to the Treatment of Rheumatoid Arthritis. New England Journal of Medicine, 2012, 367, 565-567.	13.9	27
97	The roles of IFN-Î³ versus IL-17 in pathogenic effects of human Th17 cells on synovial fibroblasts. Modern Rheumatology, 2013, 23, 1140-1150.	0.9	27
98	Targeting CD6 for the treatment of experimental autoimmune uveitis. Journal of Autoimmunity, 2018, 90, 84-93.	3.0	27
99	Etanercept-associated Pulmonary Granulomatous Inflammation in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2008, 35, 2279.2-2282.	1.0	25
100	Variation in Rheumatoid Hand and Wrist Surgery among Medicare Beneficiaries: A Population-based Cohort Study. Journal of Rheumatology, 2015, 42, 429-436.	1.0	25
101	The Human 4F2 Antigen: Evidence for Cryptic and Noncryptic Epitopes and for a Role of 4F2 in Human T Lymphocyte Activation. Cellular Immunology, 1994, 154, 253-263.	1.4	24
102	A polymorphism in the interleukin-4 receptor affects the ability of interleukin-4 to regulate Th17 cells: a possible immunoregulatory mechanism for genetic control of the severity of rheumatoid arthritis. Arthritis Research and Therapy, 2011, 13, R15.	1.6	24
103	Are Th17 Cells an Appropriate New Target in the Treatment of Rheumatoid Arthritis?. Clinical and Translational Science, 2010, 3, 319-326.	1.5	23
104	Activation of the Thromboxane A2 Receptor by 8-Isoprostane Inhibits the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Scleroderma. Journal of Investigative Dermatology, 2015, 135, 3153-3162.	0.3	23
105	Inflammatory properties of inhibitor of DNA binding 1 secreted by synovial fibroblasts in rheumatoid arthritis. Arthritis Research and Therapy, 2016, 18, 87.	1.6	23
106	CD6 dependent interactions of T cells and keratinocytes: functional evidence for a second CD6 ligand on Î³-interferon activated keratinocytes. Immunology Letters, 1997, 58, 9-14.	1.1	22
107	Evidence for the expression of a second CD6 ligand by synovial fibroblasts. Arthritis and Rheumatism, 2000, 43, 329.	6.7	22
108	High-Throughput Profiling of Ion Channel Activity in Primary Human Lymphocytes. Analytical Chemistry, 2008, 80, 3728-3735.	3.2	22

#	Article	IF	Citations
109	Patient expectations and long-term outcomes in rheumatoid arthritis patients: results from the SARA (Silicone Arthroplasty in Rheumatoid Arthritis) study. Clinical Rheumatology, 2015, 34, 641-651.	1.0	22
110	Sevenâ€Year Outcomes of the Silicone Arthroplasty in Rheumatoid Arthritis Prospective Cohort Study. Arthritis Care and Research, 2017, 69, 973-981.	1.5	22
111	The roles of IFN-Î³ versus IL-17 in pathogenic effects of human Th17 cells on synovial fibroblasts. Modern Rheumatology, 2013, 23, 1140-50.	0.9	22
112	The Incidence of Upper and Lower Extremity Surgery for Rheumatoid Arthritis Among Medicare Beneficiaries. Journal of Bone and Joint Surgery - Series A, 2015, 97, 403-410.	1.4	21
113	SH3BP2 Gain-Of-Function Mutation Exacerbates Inflammation and Bone Loss in a Murine Collagen-Induced Arthritis Model. PLoS ONE, 2014, 9, e105518.	1.1	20
114	Lipoic acid plays a role in scleroderma: insights obtained from scleroderma dermal fibroblasts. Arthritis Research and Therapy, 2014, 16, 411.	1.6	20
115	Co-stimulation and T cells as therapeutic targets. Best Practice and Research in Clinical Rheumatology, 2010, 24, 463-477.	1.4	19
116	Citrullination: A Specific Target for the Autoimmune Response in Rheumatoid Arthritis. Journal of Immunology, 2015, 195, 5-7.	0.4	18
117	CD6 is a target for cancer immunotherapy. JCI Insight, 2021, 6, .	2.3	18
118	Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis. Arthritis Research and Therapy, 2021, 23, 10.	1.6	18
119	Localization, Shedding, Regulation and Function of Aminopeptidase N/CD13 on Fibroblast like Synoviocytes. PLoS ONE, 2016, 11, e0162008.	1.1	18
120	Transforming growth factor Î² activated kinase 1: a potential therapeutic target for rheumatic diseases. Rheumatology, 2017, 56, kew301.	0.9	17
121	Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study. Seminars in Arthritis and Rheumatism, 2020, 50, 228-236.	1.6	17
122	Interferon-stimulated GTPases in autoimmune and inflammatory diseases: promising role for the guanylate-binding protein (GBP) family. Rheumatology, 2021, 60, 494-506.	0.9	17
123	Fine Mapping of Monoclonal Antibody Epitopes on Human von Willebrand Factor Using a Recombinant Peptide Library. Thrombosis and Haemostasis, 1992, 67, 166-171.	1.8	17
124	Real time visualization of cancer cell death, survival and proliferation using fluorochrome-transfected cells in an IncuCyteÂ® imaging system. Journal of Biological Methods, 2020, 7, e133.	1.0	17
125	Immediate hypersensitivity reaction to cyclophosphamide. Arthritis and Rheumatism, 1994, 37, 1101-1104.	6.7	16
126	Cytokine production by dendritic cells genetically engineered to express IL-4: induction of Th2 responses and differential regulation of IL-12 and IL-23 synthesis. Journal of Gene Medicine, 2005, 7, 869-877.	1.4	15

#	Article	IF	Citations
127	Attenuation of Murine Collagenâ€Induced Arthritis by Targeting <scp>CD</scp>6. Arthritis and Rheumatology, 2020, 72, 1505-1513.	2.9	15
128	Secondary immune amplification following live poliovirus immunization in humans. Clinical Immunology and Immunopathology, 1987, 44, 321-328.	2.1	11
129	An Anti-CD2 Monoclonal Antibody That Both Inhibits and Stimulates T Cell Activation Recognizes a Subregion of CD2 Distinct from Known Ligand-Binding Sites. Cellular Immunology, 1993, 150, 235-246.	1.4	11
130	Angiogenic and Arthritogenic Properties of the Soluble Form of CD13. Journal of Immunology, 2019, 203, 360-369.	0.4	11
131	Inhibition of bromodomain extraterminal histone readers alleviates skin fibrosis in experimental models of scleroderma. JCI Insight, 2022, 7, .	2.3	11
132	Activation of human T cell clones through the UM4D4/CDw60 surface antigen. Cellular Immunology, 1990, 128, 480-489.	1.4	10
133	Regulatory T cells in rheumatoid arthritis. Current Rheumatology Reports, 2008, 10, 405-412.	2.1	10
134	The Effect of Swan Neck and Boutonniere Deformities on the Outcome of Silicone Metacarpophalangeal Joint Arthroplasty in Rheumatoid Arthritis. Plastic and Reconstructive Surgery, 2013, 132, 597-603.	0.7	9
135	Differences between the United States and the United Kingdom in the treatment of rheumatoid arthritis: analyses from a hand arthroplasty trial. Clinical Rheumatology, 2010, 29, 363-367.	1.0	8
136	Regulation of Th17 Maturation by Interleukin 4. Critical Reviews in Immunology, 2013, 33, 379-387.	1.0	7
137	Noxa in rheumatic diseases: present understanding and future impact. Rheumatology, 2014, 53, 1539-1546.	0.9	7
138	Rheumatoid Arthritisâ€"Heresies and Speculations. Perspectives in Biology and Medicine, 1997, 40, 479-491.	0.3	6
139	Absence of complement component 3 does not prevent classical pathwayâ€"mediated hemolysis. Blood Advances, 2019, 3, 1808-1814.	2.5	6
140	Soluble CD13 induces inflammatory arthritis by activating the bradykinin receptor B1. Journal of Clinical Investigation, 2022, 132, .	3.9	6
141	Reflecting on Early Arthritis. Journal of Rheumatology, 2012, 39, 2059-2061.	1.0	5
142	Response to comment on â€œSynovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritisâ€• Science Immunology, 2018, 3, .	5.6	5
143	Editorial: Immunomodulatory Functions of Fibroblast-like Synoviocytes in Joint Inflammation and Destruction during Rheumatoid Arthritis. Frontiers in Immunology, 2020, 11, 955.	2.2	5
144	Citrullinated Inhibitor of <scp>DNA</scp> Binding 1 Is a Novel Autoantigen in Rheumatoid Arthritis. Arthritis and Rheumatology, 2019, 71, 1241-1251.	2.9	4

#	Article	IF	Citations
145	Mouse CD6: sequence of cDNA and expression of mRNA. Immunology Letters, 1996, 49, 133-137.	1.1	3
146	Interactions between T cells and synovial fibroblasts. Modern Rheumatology, 2000, 10, 16-18.	0.9	3
147	The role of CD6 in autoimmune diseases. Cellular and Molecular Immunology, 2018, 15, 1001-1002.	4.8	3
148	Xenogeneic cells and superantigen induce human T-cell activation in the absence of T-cell recognition of xenoantigen. Translational Research, 2003, 142, 149-157.	2.4	1
149	Unity in the field of rheumatology: The role of the ACR. Arthritis and Rheumatism, 2009, 60, 313-316.	6.7	1
150	Treatment for Rheumatic Disorders. New England Journal of Medicine, 2006, 354, 1322-1323.	13.9	0
151	The past and the future ofArthritis & Rheumatism: A view from the american college of rheumatology. Arthritis and Rheumatism, 2008, 58, S7-S10.	6.7	0
152	The future of ILAR. Clinical Rheumatology, 2009, 28, 493-494.	1.0	0
153	Preface. Rheumatic Disease Clinics of North America, 2010, 36, xiii-xiv.	0.8	0
154	Treg cells to the rescue. Arthritis and Rheumatism, 2012, 64, 2426-2428.	6.7	0
155	Current and future approaches to the treatment of immunologic diseases: new targets and new therapeutic agents. Translational Research, 2015, 165, 251-254.	2.2	0
156	C3 as a potential target for treating complement-mediated hemolysis. Molecular Immunology, 2018, 102, 183.	1.0	0
157	Divergence of the systemic immune response following oral infection with distinct strains ofPorphyromonas gingivalis. Molecular Oral Microbiology, 2012, , n/a-n/a.	1.3	0
158	Modulating myofibroblast transition in systemic sclerosis through inhibition of Rho/MRTF regulated transcription (1054.9). FASEB Journal, 2014, 28, 1054.9.	0.2	0
159	CD6-Targeted Antibody-Drug Conjugate As a Potential Therapeutic Agent for T Cell Lymphomas. Blood, 2021, 138, 1193-1193.	0.6	0
160	A CD6-Targeted Antibody-Drug Conjugate As a Potential Therapy for T Cell-Mediated Disorders. Blood, 2021, 138, 3817-3817.	0.6	0